Long-acting intranasal insulin for the treatment of delirium-a randomised clinical trial.

ABSTRACT:

Background

Delirium affects up to 25% of hospitalised older patients; however, there are no effective pharmacological treatments. Accumulating evidence of brain insulin resistance and altered cerebral glucose metabolism during delirium present a promising therapeutic target.

Objective

To assess the safety and efficacy of intranasal insulin in the treatment of delirium.

Design

Single-centre, randomised, double-blind, placebo-controlled trial.

Setting

Two geriatric medicine wards in a tertiary hospital.

Participants

100 patients aged over 64 years presenting to hospital and admitted under geriatric medicine with delirium.

Interventions

Participants were randomised in a 1:1 ratio to receive 20 IU of long-acting insulin or placebo intranasally twice d

SUBMITTER: Nitchingham A 

PROVIDER: S-EPMC12526039 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature